A bid by GSK Plc (NYSE:GSK) and other pharmaceutical companies to halt over 70,000 lawsuits in Delaware concerning the discontinued heartburn drug Zantac has gained support from prominent U.S. industry groups. These groups, including the United States Chamber of Commerce and Pharmaceutical Research and Manufacturers of America, argue that allowing the lawsuits to proceed jeopardizes Delaware’s business-friendly reputation, Reuters reported. Related: Pfizer Agrees To Settle Over 10,000 Lawsuits About Cancer Risks Associated With Discontinued Heartburn Drug Zantac. The report noted that in a friend-of-the-court brief filed to the Delaware Superior Court, these groups ...